Global Neoantigen Targeted Therapies Market Insights (2019-2030): Industry Overview, Publications, Patents, Funding & Investments, Opportunities and Key Player ProfilesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Global Neoantigen Targeted Therapies Market Insights (2019-2030): Industry Overview, Publications, Patents, Funding & Investments, Opportunities and Key Player ProfilesGlobeNewswireJanuary 2, 2020ReblogShareTweetShareDublin, Jan. 02, 2020 (GLOBE NEWSWIRE) -- The "Global Neoantigen Targeted Therapies Market Insights (2019-2030)" report has been added to ResearchAndMarkets.com's offering.Global Neoantigen Targeted Therapies Market Insights (2019-2030) features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. One of the key objectives of the report was to estimate the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across:[A] different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others)[B] type of treatment (personalized and off-the-shelf)[C] type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy)[D] route of administration (intradermal, intravenous, subcutaneous, and others)[E] key geographical regions (US, EU5 and rest of the world).In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.In addition to other elements, the study includes:A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.An in-depth analysis of the various patents that have been filed/granted related to neoantigens until April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.Key Topics Covered 1. PREFACE2. EXECUTIVE SUMMARY3. INTRODUCTION3.1. Chapter Overview3.2. Concept of Immunotherapy3.3. History of Cancer Immunotherapy3.4. Limitations of Cancer Immunotherapy3.5. Targeting Tumor-Specific Neoantigens3.5.1. Types of Neoantigens3.5.2. Role of Neoantigens in Cancer Immunotherapy3.5.3. Neoantigen Targeted Therapies3.5.3.1. Identification and Selection of Neoantigens3.5.3.2. Delivery of Neoantigen Targeted Therapies3.6. Key Challenges and Future Perspectives4. MARKET OVERVIEW4.1. Chapter Overview4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline4.3. Neoantigen Targeted Therapies: Pipeline Analysis4.4. Neoantigen Targeted Therapies: List of Drug Developers4.5. Grid Analysis: Analysis by Target Disease Indication, Company Size and Location5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES5.1. Chapter Overview5.2. Bavarian Nordic5.3. Genocea Biosciences5.4. Gradalis5.5. Immunicum5.6. Immunovative Therapies5.7. Iovance Biotherapeutics5.8. MediGene5.9. Neon Therapeutics6. PUBLICATION ANALYSIS6.1. Chapter Overview6.2. Methodology6.3. Neoantigen Targeted Therapies: List of Publications7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. Neoantigen Targeted Therapies: Patent Analysis7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis8. PARTNERSHIPS AND COLLABORATIONS8.1. Chapter Overview8.2. Partnership Models8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations9. FUNDING AND INVESTMENT ANALYSIS9.1. Chapter Overview9.2. Types of Funding9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis9.4. Concluding Remarks10. MARKET FORECAST AND OPPORTUNITY ANALYSIS10.1 Chapter Overview10.2. Key Assumptions and Forecast Methodology10.3. Global Neoantigen Targeted Therapies Market, 2019-203011. CONCLUDING REMARKS12. EXECUTIVE INSIGHTS12.1. Chapter Overview12.2. AIVITA Biomedical12.3. BioLineRx12.3. VAXIMM13. APPENDIX 1: TABULATED DATA14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
5AM VenturesAbbVie VenturesAbingworthAbu Dhabi Investment AuthorityAccelerate NY Seed FundAccelovanceAccess IndustriesAchilles TherapeuticsAdage Capital ManagementAdaptive BiotechnologiesAduro BiotechAdvaxisAgalimmuneAgenusAgeo Central General HospitalAgreen BiotechAisling CapitalAIVITA BiomedicalAlbion CapitalAlexandria Venture InvestmentsAlexion PharmaceuticalsAllscriptsAMAL TherapeuticsAmgen VenturesAndera PartnersApexigenArbutus BiopharmaARCH Venture PartnersArcus BiosciencesArrowMark PartnersAsia GenomicsAstellas PharmaAstraZenecaAT ImpfAtlas VentureBaillie GiffordBain Capital Life SciencesBavarian NordicBB BiotechBeth Israel Deaconess Medical CenterBGI AmericasBill & Melinda Gates FoundationBioClubBioLife SolutionsBioLineRxBioMedPartnersBioNJBioNTechBlackBerry Partners FundBlackstonebluebird bioBoehringer Ingelheim Venture FundBpifranceBrightPath BiotherapeuticsBristol-Myers SquibbBroad InstituteBroadfin CapitalButton CapitalBVF PartnersCaladrius BiosciencesCalifornia Technology VenturesCanaan InvestmentCancer Prevention and Research Institute of TexasCancer Research TechnologyCasdin CapitalCatalentCelgeneCellular BiomedicineCharles River LaboratoriesChartwaveChildren's Hospital of Orange CountyChina Medical SystemClal Biotechnology IndustriesClarus VenturesClough Capital PartnersComecerCormorant Asset ManagementCRISPR TherapeuticsCryoportCTI Life SciencesCureVacCyTIXCytovance BiologicsDana-Farber Cancer InstituteDATUMDecheng Capitaldievini Hopp BiotechDroia Oncology VenturesEcoR1 CapitalEDBIEffimuneEIC SME InstrumentEli LillyELMA InvestmentsEMD MilliporeEpiVax OncologyEUFETSEuropean Investment BankEvaxion BiotechF-Prime CapitalFidelity InvestmentsFlow PharmaForbionForesite CapitalFranklin AdvisersFrazier Healthcare PartnersGenentechGeneos TherapeuticsGenocea BiosciencesGeorgetown UniversityGlobeImmuneGoogle VenturesGradalisGrey Wolf TherapeuticsGritstone OncologyHangzhou Neoantigen TherapeuticsHeat BiologicsHelmholtz Zentrum MnchenHelsinn GroupHengRui YuanZheng BiotechnologyHercules CapitalHigh-Tech GrnderfondsHillhouse Capital GroupIcahn School of Medicine at Mount SinaiIDG CapitalImmaticsImmune DesignImmuNextImmunicumImmunomic TherapeuticsImmunovative TherapiesIMV TechnologiesInfinity PharmaceuticalsInnovate UKInnovation Fund DenmarkInovio PharmaceuticalsInstitut MrieuxIntrexonInvestsudIovance BiotherapeuticsISA PharmaceuticalsJanssen PharmaceuticalsJanus Capital ManagementJanus Henderson InvestorsJennison AssociatesJohnson & Johnson DevelopmentKanagawa Cancer CenterKarolinska University HospitalKeiretsu ForumKhoen Ken Medical CenterKuwait Investment AuthorityLa Jolla Institute for Allergy and ImmunologyLeerink PartnersLeiden University Medical CenterLevel One PartnersLikang Life SciencesLilly Asia VenturesLSPMassachusetts General HospitalMaSTherCellMateon TherapeuticsMax Delbrck Center for Molecular Medicine in the Helmholtz AssociationMD Anderson Cancer CenterMedigeneMedImmuneMeir Medical CenterMemorial Sloan Kettering Cancer CenterMerckMeusinvestMie UniversityMiller Value PartnersMiracle Light IncubatorModerna TherapeuticsMoffitt Cancer CenterMorningside GroupMSD PartnersNantBioScienceNantCellNantWorksNateraNational Institutes of HealthNatixisNECNektar TherapeuticsNeon TherapeuticsNeoPhoreNetherlands Cancer InstituteNexImmuneNextech InvestNextWavebioNorwegian Cancer SocietyNouscomNovartisNovartis Institutes for BioMedical ResearchOhio State University Comprehensive Cancer CenterOmega FundsOmerosOncoImmunityOncos TherapeuticsOncoSec MedicalOncotest-TevaOPKO HealthOrbiMed AdvisorsORYX Translational MedicineOSE ImmunotherapeuticsPACT PharmaParker Institute for Cancer ImmunotherapyPartner Fund ManagementPaulson CapitalPCI BiotechPDC*line PharmaPelican TherapeuticsPerceptive AdvisorsPersimmunePfizer VenturesPharmaCellPharmaceutical Product DevelopmentPharmstandard InternationalPhio PharmaceuticalsPhosImmunePhyton BiotechPictetPolyBioCeptPontifaxPrecigenPrecision BioLogicProBioGenQuogue CapitalRA Capital ManagementRedmile GroupRegeneron PharmaceuticalsReplimuneRocheRTW InvestmentsRufferRutgers Cancer InstituteSailing CapitalSanquin Blood Supply FoundationSant VenturesSchroder AdveqSciVac TherapeuticsSectoral Asset ManagementSequoia Capital ChinaSGI-DNAShenzhen Yuce BiotechnologySiemensSIGMA GroupSixth Element CapitalSorgenteSpinventureSquare 1 BankStand Up To CancerStanford UniversityStemirna TherapeuticsStructured ImmunityStruengmann Family OfficeSygnature DiscoverySynconaSYZ Cell TherapyT. Rowe Price AssociatesTaiho PharmaceuticalTaiho VenturesTargovaxtellaTexas OncologyThe Column GroupThe Francis Crick InstituteThe Invus GroupThe Research Council of NorwayThird Rock VenturesThorgeneNeoTrakCelTransformational Healthcare Venture CapitalTransgeneTrianta ImmunotherapiesTrinitas Capital ManagementTurnstone BiologicsUConn HealthUniversity College LondonUniversity Hospital Southampton NHS Foundation TrustUniversity of ColoradoUniversity of LausanneUniversity of North CarolinaUniversity of WashingtonVaccibodyVaxil Bio therapeuticsVAXIMMVAXON BiotechVBI VaccinesVedantra PharmaceuticalsVerizonVersant VenturesViking Global InvestorsWallonia Biotech CoachingWashington University School of MedicineWellington PartnersWhiteRock Capital PartnersWu Capital GroupWuhan Dangdai Science & Technology IndustriesWuXi AppTecYale Cancer CenterZelluna ImmunotherapyZiopharm OncologyFor more information about this report visit https://www.researchandmarkets.com/r/johr06Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900ReblogShareTweetShareRecently ViewedYour list is empty.What to Read Next5 Things You Should Know About Spinal Muscular AtrophyThe MightyYour Yoga Session Can Banish Lower Back Pain Just as Well as Meds CanBicyclingMerck Stock Is Forming A Flat Base — But Is It Time To Take On Shares?Investor's Business DailyRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceMost romantic destinations in North America ranked: The Points GuyYahoo Finance VideoUnited pulls Boeing's 737 Max jets through June 2020Yahoo Finance Video